WNT5B

Across TCGA pan-cancer cohorts, WNT5B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated WNT5B data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher WNT5B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated WNT5B expression acts as an unfavorable survival marker.

ACC, READ, and STAD are the cancer types where WNT5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
READ	DFS	Median	All	0.182	0.819	.004	18	view →
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ESCA	DFS	Median	II,III,IV	0.210	0.525	.041	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
COAD	OS	Median	All	0.570	0.870	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

WNT5B–ACC (DFS)

Open the ACC breakdown →